The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.
Several young drug developers managed to float in the first quarter, but new issues dried up in March when coronavirus infected the markets. Is the game back on?
Mirati pulls a rabbit out of its hat, but the conference will serve up three new competitors too.
The UK biotech gets a big boost from the sale of a pan-Raf inhibitor to Jazz Pharmaceuticals, but Redx’s money worries are far from over.
Amgen has gone further than anyone before to crack KRAS, but caution is required, as efficacy might ultimately not be as positive as initial data suggest.